IDPC presents key research on how the Committee on NGOs has effectively restricted civic space for drug NGOs wishing to engage in UN proceedings, and offers key recommendations for member states as they are preparing to elect new members of the Committee on NGOs in April 2022.

UNODC explores processes of heroin manufacture, the sourcing of morphine and opium, and the drivers of the industry in the region.

The NZ Drug Foundation's analysis zooms into key questions such as changes in the domestic legal framework, impact on social equity and harm reduction.

The Forum provided a space for UN, state and civil society representatives to consider how best to progress health, human rights and development in relation to drug policies.

The American Medical Association calls for increased access to healthcare and harm reduction efforts as part of a response to the growing overdose death rates in the United States.

EHRA describe key budget advocacy initiatives and HIV donor support for them.

The second issue of CHECK is dedicated to opioid agonist therapies, featuring experiences by service providers and clients.

Shaleen Title lays out a set of policy proposals to promote the growth of a diverse and competitive market, centring consumers and public health while building on effective equity programs already at work in state markets.

Handanagic et al. provide updated prevalence estimates of HIV infection and behaviours associated with HIV infection since the last NHBS survey among people who inject drugs in 2015, and represents a snapshot of the HIV prevention landscape for people who inject drugs before the COVID-19 pandemic.

Gabri et al. conclude that changes in cannabis legislation do not have an impact on the prevalence of recreational cannabis use among youth and young adults in Europe.

Chiedozie Arum et. al. conclude that homelessness and unstable housing are associated with increased risk of HIV and HCV acquisition among people who inject drugs.

IDPC releases a user-friendly resource for people from all sectors who wish to understand the key objectives, principles and concepts relating to decriminalisation of drug use and how to advocate for it.

Collaborating under the Support. Don't Punish campaign, IDPC & ARASA provide an overview of the key questions that drug decriminalisation advocates should consider to demand reform.

Dania Putri highlights and summarises the collective efforts of Support. Don't Punish campaigners worldwide to build a future without the war on drugs, where we can all thrive.

PRI has developed the 10-point plan as a tool to provide practitioners and policy makers guidance on building and strengthening services that are flexible, non-discriminatory and better able to respond to and adapt in the face of crises.

Unlu et al. evaluate the policy opportunities and barriers (including in terms of limited awareness) for the establishment of the first drug consumption room in Finland.

IDPC and GDPO take a critical look at the narratives that the UN drug control system constructs to justify its own existence, and to create an appearance of success.

Kleinschmidt & Trenta highlight how the use of new technologies further blur the boundaries between war and law enforcement.

IDPC and APCOF summarise discussions from a multi-stakeholder meeting addressing the links between criminalisation and human rights violations, regional policy developments and avenues for future reform.

Over 100 Canadian civil society organisations formulate a platform to address the harms of criminalisation on people who use drugs.